Displaying 4 (all) recruiting clinical trials.
-
Site for The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Site for CompassHER2 RD (A011801) is a randomized trial in patients with residual disease after a predefined course of neoadjuvant HER2-directed treatment. While CompassHER2 RD ... -
Melanoma Margins Trial (MelMarT): A Phase III Multi-Centre Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
This study will determine whether there is a difference in disease free survival for patients treated with either a 1cm excision margin or 2cm margin ... -
Randomized multicenter open-label phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-positive recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second line platinum-based chemotherapy plus bevacizumab(GOG 3078)
The purposes of this study are: • To determine if mirvetuximab soravtansine (MIRV) plus BEV is effective at managing subjects' type of cancer in a maintenance ... -
A Phase 3 Randomized Placebo-Controlled Double-Blind Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type Advanced or Recurrent Endometrial Carcinoma (GOG 3083)
The purpose of this research study is to further evaluate the safety and effectiveness of selinexor for maintenance in patients with TP53 wild-type endometrial cancer.